Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas
Phase II Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas.
Recurrent Adenocarcinoma of the Pancreas|Metastatic Adenocarcinoma of the Pancreas
DRUG: Genexol-PM|DRUG: Gemcitabine
Objective response rate (ORR) as assessed by RECIST., ORR will be summarized as the percentage of participants who achieved a confirmed complete (CR) or partial response (PR) using RECIST guidelines.

Response is confirmed at least 4 weeks later., 8 weeks
Progression free survival (PFS), Time from the date of enrollment until the date of objective disease progression or the date of death.

PFS will be summarized using Kaplan-Meier methods., 2 years|Overall survival (OS), OS will be summarized using Kaplan-Meier methods., 2 years|Disease control rate (DCR), DCR is defined as the percentage of patients who have achieved complete response, partial response and stable disease, 8 weeks|Number of participants with adverse events, A adverse event (AE) is as any AE occurring or worsening on or after the first treatment of any study drug, and within 21 days after the last dose of the last study drug.

Severity grades according to NCI CTCAE version 4.0., Baseline up to Day 21 after the last dose of study treatment
The aim of the this phase II study is to assess the efficacy and safety of a combination treatment of Genexol®-PM plus gemcitabine in patients with recurrent and metastatic adenocarcinoma of the pancreas.